北清環能(000803.SZ):擬以1.254億元收購保綠特95%股權
格隆匯2月8日丨北清環能(000803.SZ)公佈,為聚焦餐廚有機廢棄物處理及廢棄食用油脂資源化利用業務整體戰略發展規劃,公司擬以現金方式收購交易對手方曹健儀、金彧如分別持有的銀川保綠特生物技術有限公司(“保綠特”或“標的公司”)48.03627%、46.96373%股權。
根據雙方於2022年2月8日在濟南歷下區簽署的《關於銀川保綠特生物技術有限公司之股權轉讓協議》,標的股權對應的轉讓價款暫定為1.254億元。
本次收購完成後,公司將持有保綠特95%的股權,保綠特將成為北清環能控股子公司,納入公司的合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.